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Surgical use of the hemostatic tissue sealant Bioglue hasbecome a widely accepted and effective method to con-trol postoperative bleeding and airway air leak (AAL).1,2However, recently emerging evidence of potential com-
plications and hazards that arise from its extensive use has raised
concerns about its clinical safety.3
Clinical Summary
A 27-year-old woman with acute viral myocarditis had severe
heart failure, sepsis, multiorgan failure, and acute hemodynamic
deterioration despite maximum medical therapy. A salvage Lev-
itronix left ventricular assist device (LVAD) was urgently im-
planted as a “bridge to decision” until the reversibility of her
condition could be clarified. However, due to poor right ventricular
functioning, a Centrimag (Levitronix, Zurich, Switzerland) right
ventricular assist device (RVAD) had to be implanted 3 days later.
Following an apparently good recovery after 2 weeks, the Levitro-
nix LVAD was upgraded to a Jarvik 2000 ventricular assist device
(Jarvik Heart, Inc, New York, NY) for longer-term support; the
RVAD was left in place due to poor right ventricular function. The
initial postoperative course was turbulent, complicated by 2 sternal
reexplorations for significant diffuse bleeding from the surface of
the right lung and chest wall (the left lung and pleura were kept
intact), which could not be controlled with diathermy or pharma-
cologic agents. A thick 5-pack layer of Bioglue sealant was applied
over the surface of the right lung and the corresponding right chest
wall to control the bleeding. Six days later, the patient had sepsis
and her hemoglobin level dropped; the chest radiographs per-
formed at this time showed progressive complete opacification of
the right hemithorax (Figure 1, A). A computed tomography (CT)
scan of the chest demonstrated a loculated fluid/blood collection in
the pleural space extending all along the chest wall and into the
oblique fissure (but no intrapleural bleed was noted) (Figure 1, B),
for which she needed another resternotomy, and Bioglue was
applied again to control the bleeding. Subsequently, her condition
started to improve, and she was weaned off the ventilator and
hemofiltration; her kidney and liver functions normalized and were
cleared of infection. Radiologic findings after the surgery, both chest
radiographs and CT scans after the evacuation of the clot, contin-
ued to show minor pleural collection, and, more importantly,
changes of patchy pulmonary fibrosis in the right lung with other
areas of segmental collapse (Figure 2, A and B). Multiple assess-
ments of the heart at a later stage showed no evidence of ventric-
ular recovery. Therefore, she was listed and urgently underwent a
transplant after 101 days of mechanical circulatory support. During
the surgery, the right pleural space was fully obliterated and severe
dense adhesions were noted with a thick layer of Bioglue. The post-
From the Departments of Cardiothoracic Transplantation and Mechanical
Circulatory Supporta and Radiology,b Royal Brompton & Harefield Hospi-
tal, NHS Trust, London, UK; and National Heart & Lung Institute,c Impe-
rial College London, London, UK
Cardiothoracic Surgery, Transplantation & Mechanical Circulatory Sup-
port, Royal Brompton & Harefield Hospital, London, UK.
Received for publication Oct 6, 2006; accepted for publication Nov 28,
2006.
Address for reprints: Saleem Haj-Yahia, MD, BSc, Royal Brompton &
Harefield NHS trust, Cardiothoracic Transplantation and Mechanical Cir-
culatory Support, Hill End Road Harefield, London UB9 6RJ, UK (E-mail:
s.haj-yahia@imperial.ac.uk).
J Thorac Cardiovasc Surg 2007;133:1387-8
0022-5223/$32.00
Copyright © 2007 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2006.11.072
Figure 1. A, A radiograph showing the progressive complete
opacification of the right hemithorax due to active postoperative
bleeding. B, CT scan of the chest on the first postoperative day
showing a loculated blood collection in the pleural space.
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operative course was uneventful and she was discharged home
42 days later. On later radiologic follow-up, the right lung re-
mained expanded but with persistent fibrosis.
Discussion
Bioglue, a 2-component tissue sealant composed of bovine serum
albumin and glutaraldehyde, has been proven effective in control-
ling bleeding after major cardiovascular surgery and in controlling
AAL following lung surgery.1,2 Along with its occasionally life-
saving properties, a number of cautionary notes have recently been
reported regarding potential complications associated with its use.3
Some of these complications related to its quick and robust sealant
and glue properties (such as acute intraoperative malfunction of
the aortic valve, Bioglue coronary embolism, aseptic mediastinal
cyst, and so on). However, other complications are related to its
compound biochemical properties. In vivo studies indicated that
polymerized Bioglue releases amounts of glutaraldehyde that are
capable of inducing cytotoxic effects.4 It has been shown that
lungs and liver tissue are particularly sensitive to its toxic effect;
therefore, Furst and Banerjee4 concluded that its use should be
restricted to aortic dissection only. Erasmi5 has described the
histopathologic findings in aortic specimens treated with Bioglue
as “severe inflammation with multiple-granulocytes and histio-
cytes and a massive foreign-body reaction with numerous multinu-
cleated giant cells.” However, Bioglue has so far been widely used
and is considered safe and effective in lung surgery as a sealant to
prevent AAL, possibly because it has been used in small amounts
and in a controlled fashion on restricted areas. In our experience,
we used Bioglue in large amounts over the surface of the lung to
control severe diffuse bleeding, which was impossible to control
using other pharmacologic or surgical means and proved to be a
lifesaving procedure in this case. However, we feel that the large
amount used in our case is probably responsible for the fibrotic
changes that occurred.
In conclusion, the use of Bioglue should be kept to the mini-
mum amount needed to achieve hemostasis or to control AAL, and
it can be considered particularly detrimental when used on lung
tissue.
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Figure 2. A, A radiograph showing patchy pulmonary fibrosis
following the application of Bioglue. B, A CT scan showing
patchy pulmonary fibrosis in the right lung with other areas of
segmental collapse following the application of Bioglue. These
fibrotic changes remained persistent on later radiologic follow.
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